16
0.00%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About OncoTherapy Science
Its shares trade on Tokyo Stock Exchange under the ticker 4564.T. It has been listed since 8 December 2003. In the fiscal year to 31 March 2026, it reported revenue of ¥808.5m and a net loss of ¥910.6m. At that date it held total assets of ¥2.36bn and shareholders' equity of ¥2.14bn.
OncoTherapy Science, Inc. engages in the research and development of antibody drugs. The company is headquartered in Kawasaki-Shi, Kanagawa-Ken. The company went IPO on 2003-12-08. The firm is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The firm operates its business in cooperation with universities and other corporations. The firm provides its licenses to pharmaceutical manufacturers. The firm also involves in T Cell Receptor(TCR) analysis business.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Dec 2003
- Employees
- 62
- Website
- oncotherapy.co.jp ↗
Leadership
Pay as last reported
- Mr. Hatsuo KatoChairman of the Board, since 2020
- Mr. Jaehyun ParkPresident, Chief Executive Officer, Chief Scientific Officer, President of Subsidiary, Representative Director, since 2018
- Mr. Junichi ShimadaDirector
- Mr. Toyomasa KatagiriIndependent Director
- Mr. Yuichi KomineIndependent Director
- Mr. Yoshio MikiIndependent Director
- Mr. Osamu NinomiyaChief Director of Administration, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- OncoTherapy Science Inc has a strong reputation for its innovative research and development efforts, continuously pushing boundaries in the field of oncology.
- The company's commitment to staying at the forefront of scientific advancements enables it to develop groundbreaking therapies that could revolutionize cancer treatment.
- OncoTherapy Science Inc possesses a robust intellectual property portfolio, safeguarding its innovative discoveries and ensuring exclusivity in the market.
- This intellectual property gives the company a competitive advantage, attracting potential partners and investors who seek to benefit from its proprietary technologies.
Weaknesses
- Despite its strengths, OncoTherapy Science Inc currently faces challenges in establishing a significant market presence.
- The company may struggle to effectively commercialize its therapies due to limited brand recognition and a comparatively smaller market share compared to established competitors.
- OncoTherapy Science Inc heavily relies on research funding to sustain its operations and drive innovation.
- Any disruption or reduction in funding sources can affect the company's ability to advance its research programs and develop new therapies, potentially hindering its growth.
Opportunities
- The increasing prevalence of cancer worldwide presents a significant opportunity for OncoTherapy Science Inc.
- As the demand for more effective and personalized cancer treatments continues to rise, the company's innovative therapies have the potential to address unmet medical needs and capture a larger market share.
- OncoTherapy Science Inc can explore strategic collaborations and partnerships with other pharmaceutical companies, academic institutions, and research centers.
- Such collaborations can provide access to additional resources, expertise, and financial support, facilitating accelerated development and commercialization of its therapies.
Threats
- The oncology market is highly competitive, with numerous established pharmaceutical companies actively researching and developing cancer treatments.
- OncoTherapy Science Inc must navigate this competitive landscape, facing challenges in gaining market share and differentiating its offerings from those of larger, well-known competitors.
- The regulatory complexities and stringent compliance requirements surrounding drug development and commercialization pose potential threats to OncoTherapy Science Inc.
- Non-compliance or delays in obtaining necessary approvals can impede the company's ability to bring its therapies to market in a timely manner, impacting its revenue generation and overall success.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.